最新消息
輝瑞與惠氏強勢結合﹕同創健康未來
強化實力、資產與人才，提高輝瑞的使命 - 利用科學與全球資源的應用令每個人在不同人生階段活得更好、更健康
在人類、動物和消費者健康範疇上建立和拓展領導地位
結合作一個鞏固平台、帶來統一和穩定的收入增長
紐約．10月16日 – 輝瑞(NYSE: PFE)今天宣佈，於昨天完成與惠氏的併購後，兩間公司開始共同營運。輝瑞現在已成為一間更多元化的健康護理公司，在已發展和新興市場供應涵蓋人類、動物和消費者保健等範疇的產品，當中包括疫苗、生物製劑、小分子及營養品。 公司除了擁有在無數增長迅速的醫療領域之藥物，更擁有龐大的產品生產線、領先的科學技術和生產能力、以及在全球健康護理界佔有舉足輕重的地位。
「合併後的輝瑞將擁有業界其中一些最好的資產、最優秀的人才、以及最龐大生產線和潛力。」輝瑞主席兼行政總裁Jeffrey B. Kindler說。「我們的任務清晰明確，就是要把這些優勢變成對我們所服務的病人、消費者及社區、以及我們的股東而言有意義的成果。在爭取最佳財務績效的同時，我們將會透過實踐公司的新承諾，包括推動保健、疾病預防和治療以滿足世界不同的健康需要，來衡量我們的成績。」
「我們很高興歡迎來自惠氏的同事加入輝瑞，惠氏人才輩出，當中有不少一流的科研人員和商業領袖。」Kindler先生續說。「讓我們感到自豪的是無論新舊同事，每一位都具備對我們業務各範疇不可或缺的寶貴技術和經驗，而且亦與我們同樣熱切地追求改善人們在人生每一階段的健康。」
營運整合與準備
自一月宣佈併購協議以來，輝瑞與惠氏的整合隊伍一直努力不懈，確保合併後的公司，在完成併購後能即時全面運作。為進一步達成這些目標，輝瑞早前宣佈研究與發展的新路向、經改良的商業運作結構，並委任高層領導人員，使其任命可於完成併購後立即生效。這些安排讓輝瑞能夠即時利用與惠氏合併帶來的好處。
「我們能夠及時完成這併購，並在合併首天便能全面運作，確切見證兩家公司整合隊伍付出的努力。」領導整合工作的輝瑞財務總監Frank D’Amelio說。「由於在整個整合過程中，維持業務連續性一直是我們最重要的目標，因此我們的領導人員和同事已準備好，並可以迅速利用輝瑞穩固的財務基礎、營運紀律和多樣化的產品選擇，繼續提升我們的表現。」
更強和更多元化的產品系列
輝瑞現在擁有的全球產品系列覆蓋廣泛而多元化，幾乎在所有主要的高增長的醫療領域都佔有領導地位。結合後的公司在生物科技、疫苗、消費者健康護理、營養品及動物健康等方面有更強實力。新公司無論在短期或長期目標中，都有條件在收入和經調整攤薄後的每股盈利方面取得持續和穩定的增長。預期在2012年，沒有任何藥物會佔合併後的公司超過一成的收入。
結合後的公司已有連串生物製藥發展計劃，幫助包括老年癡呆症、腫瘤、痛症、神經科學、糖尿病和炎症等重要疾病範疇的病人。匯集兩間公司的頂尖科研人員、領先的科學與生產能力、以及概念性驗證臨床發展中心的全球網絡，這些種種都大大增強了公司創新的能力。
靈活及以病人為本的全球營運結構
輝瑞以病人為本的人類健康產品業務、以及動物健康、消費者及營養產品業務的營運模式運作，集小型企業的具聚焦點，和靈活性及跨國公司的資源和規模於一身。這些業務現分成兩個組別，讓我們的領導層能夠找到跨業務單元的商機和應付挑戰、更能掌握企業首要關注事項、以及更有效執行我們的目標與承諾。生物製藥業務(Biopharmaceutical Businesses)單元包括了新興市場、成熟產品 、腫瘤科、基層護理及專科護理，當中包括疫苗。多元化業務(Diversified Businesses)則包括動物健康、Capsugel、消費者健康護理及營養品。
為了充分利用生物製藥研究的新機遇，輝瑞現在成立了兩個不同的研究機構。PharmaTherapeutics研發組將專注在小分子的發現及其相關的物理療法、BioTherapeutics研發組則集中焦點於包括疫苗的大分子研究。這兩個研究機構內的個別單位由世界級的首席科研主管領導，除了作為單一問責點，亦可為輝瑞業務發展提供正面概念驗證。
輝瑞目前在美國、歐洲、亞洲和拉丁美洲的立足點更見穩固，而且亦有更強實力幫助在中國及中東等主要新興市場的病人。
領導層
輝瑞的行政領導團隊結合了輝瑞和惠氏的領導人員，成員包括﹕
- Jeffrey B. Kindler - 主席兼行政總裁
- Frank D’Amelio - 財務總監、業務營運高級副總裁
- Mikael Dolsten - BioTherapeutics研發組總裁
- Freda Lewis-Hall - 高級副總裁、醫療總監
- Martin Mackay - PharmaTherapeutics研發組總裁
- Mary McLeod - 人力資源高級副總裁
- Ian Read - 全球生物製藥業務組別總裁
- Cavan Redmond - 多元化業務組別總裁
- Nat Ricciardi - 生產部總裁
- Bill Ringo - 業務發展、策略及創新高級副總裁
- Amy Schulman - 高級副總裁、總法律顧問
- Sally Susman - 高級副總裁、傳訊總監
除行政領導團隊外，Jeff Kindler亦成立了行政循規委員會，並由他親自主持。委員會成員將包括出任循規總監的Doug Lankler，他會向Kindler直接匯報﹔另一名成員是內部核數總監Hugh Donnelly，他會向董事局的審計委員會及Frank D’Amelio匯報。行政循規委員會成員還包括Frank D’Amelio、Ian Read、Cavan Redmond及Amy Schulman。
「輝瑞將從行政領導團隊的專才、及其成員在不同領域的豐富經驗中獲益良多。」Kindler先生說。「行政循規委員會的設立，為我們的循規基礎設施加入重要一環，並確保最高領導層能參與我們在輝瑞推行循規和誠信的工作。」
輝瑞現正就人才與地點事宜的決定作最後定案，並會盡快有效落實和推動有關決定。人才與地點事宜需視乎適用的職工委員會及/或工會諮詢及其他法律要求而定。
財務摘要
預計這次併購可在交易結束後的第二個年度裏讓輝瑞經調整和攤薄後的每股盈利帶來增值(i)。交易預計將於2012年年底前帶來大約40億美元的協同效益。連同我們計劃除了併購惠氏之外，在2011年年底前取得約20億的成本節省，這些協同效益預計可在銷售、資訊和管理運作、研發和製造方面實現。
輝瑞: 同創健康未來
在輝瑞，我們把科學與全球資源用於令人們在每個人生階段活得更好、更健康。我們致力訂立為人類和動物藥物研發和生產的品質、安全和價值的標準。我們多元化的全球健康護理產品系列涵蓋人類和動物的生物及小分子藥物及疫苗、營養品以及很多世界著名的消費者產品。每天，輝瑞的同事們在已發展和新興市場推動保健、疾病預防及治療方法的發展以及應付我們當前最棘手疾病的挑戰。配合我們作為世界領先生物製藥公司的責任，我們亦與醫療護理服務提供者、政府及本地社區合作，在世界各地支持和擴展人們獲得可靠和可負擔的醫療護理的機會。150多年來，輝瑞一直為倚靠和信賴我們的人帶來改變。如欲了解我們的承諾，請瀏覽www.pfizer.com。
惠氏目前是輝瑞全資擁有的附屬公司。在不同司法管轄區的惠氏和輝瑞部門合併可能仍屬待決，並須符合當地不同的法律及規管要求。
詳情請瀏覽www.pfizer.com。
欲知輝瑞最新動向，請瀏覽www.Twitter.com/pfizer_news。
「經調整收入」及「經調整攤薄後的每股盈利」被定義為已申報的淨收入及其組成部份、以及除盤購會計制調整、與收購相關成本、已中止營運及若干項目外的已申報攤薄後的每股盈利。根據輝瑞2008年12月31日結束的財政年度的10-K 表格中，管理層就財務狀況及營運結果的討論及分析(Management’s Discussion and Analysis of Financial Condition and Results of Operations)章節內經調整收入之描述，管理層利用經調整收入及其他因素訂定業績目標、以及衡量公司整體表現。我們相信披露這措施能加深投資者對我們業績的了解。「經調整收入」及其組成部份、以及「經調整和攤薄後的每股盈利」並非、亦不應被視為可取代美國「公認會計原則」(U.S. GAAP)計算的淨收入及其組成部份和攤薄後的每股盈利。
DISCLOSURE NOTICE: The information contained in this release is as of October 16, 2009. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments.
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “forecast” and other words and terms of similar meaning. Such statements include, but are not limited to, statements about the benefits of the acquisition of Wyeth, including future financial and operating results and cost savings, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Pfizer's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Pfizer and Wyeth will not be realized, or will not be realized within the expected time period, due to, among other things, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Pfizer's ability to accurately predict future market conditions; dependence on the effectiveness of Pfizer's and Wyeth's patents and other protections for innovative products; the success of research and development activities; decisions by regulatory authorities regarding whether and when to approve our drug applications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of our products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success of external business-development activities; competitive developments, including with respect to competitor drugs and drug candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates; the ability to successfully market both new and existing products domestically and internationally; difficulties or delays in manufacturing; trade buying patterns; the ability to meet generic and branded competition after the loss of patent protection for our products and competitor products; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; U.S. legislation or regulatory action, including legislation or regulatory action that may result from pending and possible future healthcare reform proposals, affecting, among other things, pharmaceutical product pricing, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs, the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries, direct-to-consumer advertising and interactions with healthcare professionals, and the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines; the impact of the Medicare Prescription Drug, Improvement and Modernization Act of 2003; legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access; contingencies related to actual or alleged environmental contamination; claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates; significant breakdown, infiltration or interruption of our information technology systems and infrastructure; legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection, governmental investigations, ongoing efforts to explore various means for resolving asbestos litigation, and other legal proceedings; the Company’s ability to protect its patents and other intellectual property both domestically and internationally; interest rate and foreign currency exchange rate fluctuations; governmental laws and regulations affecting domestic and foreign operations, including tax obligations and changes affecting the taxation by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals; changes in U.S. generally accepted accounting principles; uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our lenders, our customers, our suppliers and counterparties to our foreign-exchange and interest-rate agreements of the global recession and recent and possible future changes in global financial markets; any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas; growth in costs and expenses; changes in our product, segment and geographic mix; and the impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual items, including our ability to realize the projected benefits of our cost-reduction initiatives. A further list and description of risks, uncertainties, and other matters can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and in its reports on Forms 10-Q and 8-K.
